-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Kn88Hh5xobkiXksdEbFsVOPtGPXyMTArq868SltwgXtcA/m8RcYP85pYLovR65rk mzpUx1z127a0xTnsdTypoQ== 0001144204-06-044976.txt : 20061102 0001144204-06-044976.hdr.sgml : 20061102 20061102162648 ACCESSION NUMBER: 0001144204-06-044976 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20061101 FILED AS OF DATE: 20061102 DATE AS OF CHANGE: 20061102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XTL BIOPHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001023549 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51310 FILM NUMBER: 061183035 BUSINESS ADDRESS: STREET 1: KIRYAT WEIZMANN BUILDING 3 CITY: REHOVOT76100 ISRAEL STATE: L3 MAIL ADDRESS: STREET 1: KIRYAT WEIZMANN BUILDING 3 CITY: REHOVOT76100 ISRAEL STATE: L3 ZIP: 00000 6-K 1 v056325_6k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For November 1, 2006

Commission File Number: 000-51310

XTL Biopharmaceuticals Ltd. 
(Translation of registrant's name into English)

750 Lexington Avenue, 20th Floor
New York, New York 10022  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x  Form 40-F  o 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o   No x
 
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A  
 
 
 
 
 

 
xtlbio logo

XTL BIOPHARMACEUTICALS TO PRESENT AT THE RODMAN & RENSHAW HEALTHCARE CONFERENCE

NEW YORK, NEW YORK, November 1, 2006 - XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the Company’s Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 8th Annual Healthcare Conference. Mr. Bentsur’s presentation will take place on Monday, November 6, 2006 at 10:15 am EST at the New York Palace Hotel in New York City.

A live webcast of Mr. Bentsur's presentation will be available at http://www.wsw.com/webcast/rrshq10/xtl.ln/. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.
 
XTL Biopharmaceuticals Ltd. (“XTL”) is engaged in the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTL’s hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors.  XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(212)-531-5960
 
 
 
 

xtlbio logo

XTL BIOPHARMACEUTICALS LTD. ANNUAL GENERAL MEETING STATEMENT

NEW YORK, NEW YORK, November 2, 2006 - XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced that at its adjourned Annual General Meeting held yesterday, all the resolutions proposed to the shareholders were approved.
 
ABOUT XTL BIOPHARMACEUTICALS LTD.
 
XTL Biopharmaceuticals Ltd. (“XTL”) is engaged in the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTL’s hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors.  XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(212)-531-5960

 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
     
 
XTL BIOPHARMACEUTICALS LTD.
 
 		  
 		  
 
Date: November 2, 2006 By:   /s/ Ron Bentsur  
 
Ron Bentsur 
Chief Executive Officer
   

GRAPHIC 2 xtlbio.jpg GRAPHIC begin 644 xtlbio.jpg M_]C__@`(5T%.1S("_^``$$I&248``0$!`&``8```_]L`0P`0"PP.#`H0#@T. M$A$0$Q@H&A@6%A@Q(R4=*#HS/3PY,S@W0$A<3D!$5T4W.%!M45=?8F=H9SY- M<7EP9'A<96=C_]L`0P$1$A(8%1@O&AHO8T(X0F-C8V-C8V-C8V-C8V-C8V-C M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C_\``$0@`30#=`P$A M``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D*"__$`+40 M``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2U MMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ M`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(!`@0$`P0' M!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6 M)#3A)?$7&!D:)B_)&/Q]JZVLZL5&32+I2YHZA169H%%`!10`44`%%`!10`44`%% M`!10`44`%%`!7$^,5U#3KM+FUO;M+:?.5$SX1^X]@1T'L>PK6C;FLS*K?ENC M`MM>U2VN$F%]/)L.=DLC,K>Q!-=%?^&$UG;J>E7"*MU^\:.4\`G.[D9YSV]< M\]JZ)M4VI)&$4ZB:;-".TM_"&B7,ZR>=M<3_;&I_] M!&[_`._[?XTJ24[R:'4;A:*9TR+J5IX,NKVXO;@SS^6\9,Q)1-PQ@]BQGSR[A_;&I_]!&[_P"_[?XT?VQJ?_01N_\`O^W^-')'L'/+ MN']L:G_T$;O_`+_M_C7INDNTFD63R,6=H(RS,*25D;T9-MW9EMNG4T:*Q/4"B@`HH` M*JZE9)J.GSVDAPLJX!_NGJ#^!P::=G<35U8\IO+66RNY;:<8DB8J>#@^XSV/ M45U'@7562X;3)G)1P6A!_A810;:W(>7)'/7"X[Y(Y]LTE[E,'[]0]$O M+2"^MGMKE-\3XW+DC.#GJ/<5F?\`"*:)_P`^7_D5_P#&N2-2459,ZI0C)W9A M^+M$T[3=+BFL[?RY&F"$[V/&UCW/L*X^NRE)RC=G)5BHRLCTS_A%-$_Y\O\` MR*_^-9GB/P]I=CH=S\?\`Z"*TQ&R,Z&[+M%X] M>W4&944LS!0.Y.*1)(Y,^6ZMCKM.:FSM.&)=TDC!%&<9).!7JFBZS]U(P;_:Y%5+ M.Y:TG,YU5:"P%:%2#]WK^II:E_QXR?A_,55T;_`);? M\!_K66^2BDAE]/I3C+V ML6F9UJ+RZK&I3=T]S:5@Z!E.0PR#3JY#Z%--7044#*6KWMO8:;--=!&3:5$; M])"1POXUY-77AT[-G+7>J1>T743I>IPW6T,JG#@J"=IZX]#C_.,UZI#*EQ!' M-$VZ.10ZG&,@C(J<1'5,J@]&B2BN8Z#F/'W_`"!(?^OA?_06K@*[J'P''6^, M]FK%\7_\BS=_\`_]#6N.'Q(ZI_"SS.O6=%_Y`EA_U[Q_^@BNG$;(YZ&[+M%< MAU'.W7_'U-_OM_.M^)/+B1,YVJ!FNFN_=1X>5Q_>U7_6['UBZLH6[!`Y903_ M`"_I44/C.C-DGA_FBW<-OT?=NW$JN3G/.146C?\`+;_@/]:O_EW+U,6[XVD_ M[OZ,J3-]JOC@@!W"@@=N@-;]*OHHHK*WSRJU.[_S_P`PK(UB,+,D@Q\PP>/3 M_P#74T'[YOFD>;#-]K?Y%[3V+6418Y."/R.*LUG/XF=6&;=&#?9?D%%2;GF_ MBS6CJ=^887/V6`E5`8$.PSEN/T]OJ:I:#I9U?4TMBQ6,`O(RXR%'IGW('XUW MKW('"_?F5]2LGT[4)[20Y:)L`_WAU!_$8-=7X%UANR[17(=1SM MU_Q]3?[[?SKHJZ:^T3Q)<\@$D?7_`/544?C1TYFTL++Y?F6]-_X\8_Q_F:M5 M$_B9T87^!#T7Y!7.^+]:.FV0MK=RMU<#AE8`QKW/KSR!^//%.G'FDD:U)@KRN97CO3/-MH]1C'S M0XCD_P!TG@]>Q/I_%[5Q,,KV\\1B11_"PZCJ<>H]B*OUQ25FT=D7=7.8\??\@2'_`*^%_P#06K@*[:'P M')6^,]FK%\7_`/(LW?\`P#_T-:XX?$CJG\+/,ZUH?$VKV\$<,5WMCC4(H\M# M@`8':O0E!2W.&,G'8?\`\)7K?_/[_P"0D_PH_P"$KUO_`)_?_(2?X5'L8=B_ M:S[G16DDES;0RR$O+*BLQ`ZDCT%;5EJ$7DK'*0C+A0>Q%*K#FC9=#Q<#B(T* M\G/9WU+$M_;Q#_6!SZ)S_P#6K)C5[Z\^;JQRQ'85G2BX)R9T8^O#$SA0IN^N MO]?>:NI?\>,GX?S%5=&_Y;?\!_K41_@LZ*W_`",:?I_\D,U6V82F=02C8W>Q MJ>TU)'0+.P5^F<<'_"K,9,JMZ!>:QY M'DO;K@[&/+%+ ML%8%_P"$[+4+V6ZN+BZ,DAR=K*`.P`^7T`JH3<'="G!35F)9^#]-L[N*Y62X M=HF#JKN,9'3H!WKH*)SY_.M6IE)R=V M5&/*K(H:OI4&L6JV]R\BHKAP8R`JNI6,6I6,EI.SK')C)0@'@@]_I6:=G[_P"^U_\`B:/^$&TS_GO= M_P#?:_\`Q-'UB0>PB:]KI%O:K"L;RD1!0NXCG'KQ4EQIT,SL^61CZ=,^M+V\ MKW.1Y91<'"[U=R%-(0'YY6(]ABKL,$4`(B0+GK14JN>G0>$RZGAWS-WD+/$L M\31L2`WI4=K:1VN[RRQW8SN-0IM1Y3IEAH2K*N]UIY=?\R<@,""`0>"#5&32 MH6R8V9#V'4"G"HX;&>+P<,2O>T:V8Q-(0'YY6(]ABKL4$4(_=QJO;/?\ZJI5 M<]#+"9=3P[YGJR6BL3T0HH`**`"B@`HH`**`"B@`HH`**`"B@`HH`**`"B@` 'HH`**`/_V3\_ ` end -----END PRIVACY-ENHANCED MESSAGE-----